Evaluation of the Relationship Between Initial Lymphocyte Count and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukaemia Patients
Introduction:Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm characterised by the overproduction of haematopoietic cells in the granulocytic series, involving translocation of chromosomes 9 and 22. The first tyrosine kinase inhibitor, imatinib, used in the treatment of CML, represen...
Main Authors: | İstemi Serin, Mehmet Hilmi Doğu, Vahit Can Çavdar, Elif Suyani |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Yayinevi
2020-11-01
|
Series: | İstanbul Medical Journal |
Subjects: | |
Online Access: |
http://istanbulmedicaljournal.org/archives/archive-detail/article-preview/evaluation-of-the-relationship-between-nitial-lymp/41823
|
Similar Items
-
A case of double leukemia: chronic myeloid leukemia intolerant to imatinib and chronic lymphocytic leukemia
by: Miriana Rocchi
Published: (2015-10-01) -
Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01) -
Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
by: Esma Bilajac, et al.
Published: (2022-12-01) -
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation
by: E Loveman, et al.
Published: (2012-05-01) -
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
by: G Rogers, et al.
Published: (2012-04-01)